These findings provide an indication that by evaluating high levels of plasma WARS1 upon ICU admission, sepsis patients who would benefit from an anti-WARS1 MAb injection may be identified and administered the therapeutic at the appropriate stage of sepsis. This evidence concerns the gene WARS1 and Sepsis.